Rubicon Research Ltd Q1 FY27 Earnings Analysis

- Strong growth trajectory continues with broad-based demand across the product portfolio. - Revenue for Q4 FY26 showed a 44% year-on-year growth, with sequential growth of around 8%. - The company expects sustained demand and increased outsourcing for at least the next couple of quarters. - Upcoming 24 product filings under US FDA review indicate a robust pipeline, with launches expected over the next 12 to 18 months. - Pithampur facility ramp-up anticipated within 12 to 18 months post FDA inspection, enhancing internal manufacturing capacity. - Capex of around INR 300 crores planned over the next two years to support growth and capacity expansion. - The company aims to maintain EBITDA margins at 22-23% while expanding sales. - Confident in beating overall industry growth (IPM growth) by fiscal 2028.

- Rubicon Research demonstrated strong growth momentum in Q4 FY26 with revenue up 44% YoY and EBITDA up 67% YoY; PAT grew 112% YoY. - For FY26, revenue grew 37%, EBITDA 52%, and PAT 84%, indicating healthy profitability trends. - Management expects sustained revenue growth ahead driven by broad-based demand and new product launches (24 products under US FDA review). - EBITDA margin guidance is maintained at 22%-23%, considering ongoing expenses (ESOP, Arinna acquisition, Pithampur costs) and potential raw material/logistics cost volatility. - R&D productivity stands at 5.9x with continued focus on specialty and drug-device combination portfolio, underpinning quality growth. - Capex of around INR 300 crores is planned over the next two years to support capacity expansion, especially the ramp-up of Pithampur site expected within 12-18 months. - Despite recent increases, finance costs may not decrease soon due to partial debt funding of acquisitions. - Overall, the company targets sustained profitable growth with stable margins and expanding pipeline.

- Capex guidance for the next two years is projected to be close to INR 300 crores across various sites (Page 14). - The Pithampur facility will be ramped up in the coming year to meet the strong demand (Page 14). - Capex philosophy: capex will lag sustained demand; capex incurred only after proven long-term demand to avoid overcapacity (Page 14). - Recent capex includes acquisition of the Pithampur facility and additional investments (Page 4). - Part of cash outflow in investing activities includes capex of INR 800 million along with acquisition and other inorganic outflows (Page 4). - The company is keeping a "war chest" for any interesting inorganic acquisition opportunities, aligned with their RHP strategy, indicating potential future strategic investments (Page 17).

- Rubicon Research Limited raised around INR 161 crores through IPO, with approximately INR 100 crores still unutilized as of May 2026. - The unutilized IPO funds are partly planned for use in the Arena acquisition. - Additionally, the Arena acquisition has been partly funded through debt of around INR 75 crores. - The company is maintaining a "war chest" for any attractive inorganic acquisition opportunities as stated in their RHP strategy. - No specific new acquisitions or fundraising plans (debt or equity) for FY 2027 have been disclosed; management will announce when there is certainty about any future transactions. - Finance costs are currently elevated due to remaining debt repayments and financing of factoring receivables, as well as debt used for recent acquisitions. - Finance cost may not reduce immediately due to recent acquisition-related debt.

- Rubicon Research has a strong revenue visibility with broad-based demand across its portfolio. - There are 24 products currently under review with the US FDA, indicating a robust pending approval pipeline. - These 24 products under FDA review are expected to launch over the next 12 to 18 months, contributing to growth. - Inventory levels have increased as part of preparation for upcoming product launches. - The company is ramping up capacity, especially at its Pithampur facility, expected to reach decent utilization within 12 to 18 months post-FDA inspection. - Demand is expected to be sustained and growing, necessitating outsourced manufacturing until internal capex expansions are fully operational.